Akums Drugs (India) Performance
| AKUMS Stock | 672.10 32.00 5.00% |
The firm shows a Beta (market volatility) of 0.0089, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Akums Drugs' returns are expected to increase less than the market. However, during the bear market, the loss of holding Akums Drugs is expected to be smaller as well. At this point, Akums Drugs has a negative expected return of -0.39%. Please make sure to confirm Akums Drugs' total risk alpha, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to decide if Akums Drugs performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Akums Drugs and has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Pharma stocks soar 6 percent as investors respond to double dose of Good News - Business Standard | 09/10/2024 |
2 | Akums Drugs Stocks Secures exclusive rights to Triple Hairs products in India - BusinessLine | 10/16/2024 |
3 | Akums Drugs tanks 10, falls below issue price on weak Q2 earnings - Business Standard | 11/12/2024 |
4 | Akums Drugs shares hit second upper circuit, reach new high heres why - Business Standard | 11/20/2024 |
Akums |
Akums Drugs Relative Risk vs. Return Landscape
If you would invest 88,345 in Akums Drugs and on August 28, 2024 and sell it today you would lose (21,135) from holding Akums Drugs and or give up 23.92% of portfolio value over 90 days. Akums Drugs and is generating negative expected returns and assumes 3.2259% volatility on return distribution over the 90 days horizon. Simply put, 28% of stocks are less volatile than Akums, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Akums Drugs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akums Drugs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akums Drugs and, and traders can use it to determine the average amount a Akums Drugs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1203
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AKUMS |
Estimated Market Risk
| 3.23 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Akums Drugs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akums Drugs by adding Akums Drugs to a well-diversified portfolio.
Akums Drugs Fundamentals Growth
Akums Stock prices reflect investors' perceptions of the future prospects and financial health of Akums Drugs, and Akums Drugs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akums Stock performance.
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 134.21 B | ||||
| Shares Outstanding | 157.39 M | ||||
| Price To Book | 18.53 X | ||||
| Price To Sales | 3.09 X | ||||
| Revenue | 42.31 B | ||||
| EBITDA | 4.96 B | ||||
| Book Value Per Share | 49.59 X | ||||
| Earnings Per Share | 0.08 X | ||||
About Akums Drugs Performance
By examining Akums Drugs' fundamental ratios, stakeholders can obtain critical insights into Akums Drugs' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Akums Drugs is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Akums Drugs is entity of India. It is traded as Stock on NSE exchange.Things to note about Akums Drugs performance evaluation
Checking the ongoing alerts about Akums Drugs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akums Drugs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akums Drugs generated a negative expected return over the last 90 days | |
| Akums Drugs has high historical volatility and very poor performance | |
| About 83.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Akums Drugs shares hit second upper circuit, reach new high heres why - Business Standard |
- Analyzing Akums Drugs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akums Drugs' stock is overvalued or undervalued compared to its peers.
- Examining Akums Drugs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akums Drugs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akums Drugs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akums Drugs' stock. These opinions can provide insight into Akums Drugs' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Akums Stock
Akums Drugs financial ratios help investors to determine whether Akums Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Akums with respect to the benefits of owning Akums Drugs security.